PE20010207A1 - Uso de agonistas o antagonistas de estrogenos por medios transdermicos - Google Patents

Uso de agonistas o antagonistas de estrogenos por medios transdermicos

Info

Publication number
PE20010207A1
PE20010207A1 PE2000000523A PE0005232000A PE20010207A1 PE 20010207 A1 PE20010207 A1 PE 20010207A1 PE 2000000523 A PE2000000523 A PE 2000000523A PE 0005232000 A PE0005232000 A PE 0005232000A PE 20010207 A1 PE20010207 A1 PE 20010207A1
Authority
PE
Peru
Prior art keywords
antagonists
transdermal
estrogen agonists
phenyl
day
Prior art date
Application number
PE2000000523A
Other languages
English (en)
Inventor
Silva-Jardine Paul Andrew Da
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010207A1 publication Critical patent/PE20010207A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE AL USO DE UN AGONISTA O ANTAGONISTA DE ESTROGENOS DE FORMULA I, DONDE: G ES PIRROLIDIL, PIPERIDIL, GRUPO a; R ES H, OH, F, Cl O DE PREFERENCIA (-)-CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TETRAHIDRONAFTALEN-2-OL, EL CUAL SE PUEDE UTILIZAR POR MEDIOS TRANSDERMICOS TAL COMO UN PARCHE TRASNDERMICO O UNA COMPOSICION DE HIDROGEL EN UNA CANTIDAD DE 10µg/DIA-500µg/DIA POR UN PERIODO DE TRES A CATORCE DIAS; SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON UN DESEQUILIBRIO DE ESTROGENOS COMO CANCER, OSTEOPOROSIS, OBESIDAD, ENFERMEDAD CARDIOVASCULAR
PE2000000523A 1999-06-01 2000-05-31 Uso de agonistas o antagonistas de estrogenos por medios transdermicos PE20010207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13716499P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
PE20010207A1 true PE20010207A1 (es) 2001-02-28

Family

ID=22476088

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000523A PE20010207A1 (es) 1999-06-01 2000-05-31 Uso de agonistas o antagonistas de estrogenos por medios transdermicos

Country Status (16)

Country Link
EP (1) EP1057480B1 (es)
JP (1) JP2001002588A (es)
KR (1) KR20010029770A (es)
AT (1) ATE269698T1 (es)
AU (1) AU3781000A (es)
CA (1) CA2310272A1 (es)
CO (1) CO5170459A1 (es)
DE (1) DE60011710T2 (es)
DK (1) DK1057480T3 (es)
ES (1) ES2220346T3 (es)
HU (1) HUP0002085A3 (es)
IL (1) IL136376A0 (es)
NZ (1) NZ504868A (es)
PE (1) PE20010207A1 (es)
PT (1) PT1057480E (es)
ZA (1) ZA200002693B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CA2380769A1 (en) * 2000-06-01 2001-12-06 Watson Pharmaceuticals, Inc. Transdermal delivery of lasofoxifene
US20140067048A1 (en) 2012-09-06 2014-03-06 Edwards Lifesciences Corporation Heart Valve Sealing Devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment

Also Published As

Publication number Publication date
KR20010029770A (ko) 2001-04-16
EP1057480B1 (en) 2004-06-23
PT1057480E (pt) 2004-10-29
HUP0002085A2 (en) 2001-03-28
ES2220346T3 (es) 2004-12-16
DK1057480T3 (da) 2004-11-08
HUP0002085A3 (en) 2002-09-30
CA2310272A1 (en) 2000-12-01
NZ504868A (en) 2001-09-28
IL136376A0 (en) 2001-06-14
DE60011710D1 (de) 2004-07-29
HU0002085D0 (en) 2000-08-28
AU3781000A (en) 2000-12-07
ATE269698T1 (de) 2004-07-15
JP2001002588A (ja) 2001-01-09
ZA200002693B (en) 2001-11-30
EP1057480A2 (en) 2000-12-06
EP1057480A3 (en) 2002-01-09
CO5170459A1 (es) 2002-06-27
DE60011710T2 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
Jain et al. Identification and Structure− Activity Relationships of Chromene-Derived Selective Estrogen Receptor Modulators for Treatment of Postmenopausal Symptoms
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
CR8544A (es) Compuestos de quinolina sustituidos
BRPI0510604B8 (pt) composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
UY30610A1 (es) Moduladores de mglur5
BRPI0511979A (pt) derivados de triazóis substituìdos como antagonistas de oxitocina, composição farmacêutica compreendendo os referidos derivados, bem como uso dos mesmos
TW200745122A (en) New compounds I
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
PL1827427T3 (pl) Pochodne aryloksyetyloamin i fenylopiperazyn wykazujące połączenie częściowego agonizmu wobec receptorów dopaminowych D2 oraz hamowania wychwytu zwrotnego serotoniny
AR051043A1 (es) Forma cristalina de clorhidrato de (3-cian-1h-indol-7il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
AR046756A1 (es) Derivados de hidronopol como agonistas de receptores orl-1 humanos.
UY28911A1 (es) Profármacos de esteroides con acción androgénica
TW200613315A (en) Estradiol prodrugs
PE20010207A1 (es) Uso de agonistas o antagonistas de estrogenos por medios transdermicos
TW200612962A (en) Estriol and estetrol prodrugs
TW200745133A (en) New compounds II
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
PE20010680A1 (es) Uso de lasofoxifeno

Legal Events

Date Code Title Description
FC Refusal